Acta Neurologica Belgica

, Volume 113, Issue 4, pp 469–475 | Cite as

Long-term effects of injection of botulinum toxin type A combined with home-based functional training for post-stroke patients with spastic upper limb hemiparesis

  • Toru Takekawa
  • Masahiro Abo
  • Kazuaki Ebihara
  • Kensuke Taguchi
  • Yousuke Sase
  • Wataru Kakuda
Original Article

Abstract

The aim of this study was to assess the effects of botulinum toxin type A (BoNT-A) injection with home-based functional training for passive and active motor function, over a 6-month period in post-stroke patients with upper limb spasticity. We studied 190 patients with at least 6-month history of stroke. They received injections of BoNT-A in upper limb muscles and detailed one-to-one instructions for home-based functional training. At baseline (before therapy), and at 1-, 3- and 6-month follow-up, Fugl-Meyer assessment (FMA) and Wolf motor function test (WMFT) were used to assess active motor function, the modified Ashworth scale (MAS) for assessment of spasticity, and the range of motion (ROM) for passive motor function. The total score for upper limb and scores of categories A and B of the FMA increased significantly at 1, 3 and 6 months, while the FMA score for category D increased significantly at 3 and 6 months, but not at 1 month. Significant decreases in the MAS scores were noted in all muscles examined at 1, 3 and 6 months, compared with baseline. The ROM for elbow joint extension significantly improved at 1, 3, and 6 months, while that for wrist joint extension increased significantly at 1 month, but not 3 or 6 months, compared with baseline. The results suggest that comprehensive improvement of motor function requires improvement of motor function in the proximal part of the upper limb and that BoNT-A followed by rehabilitation reduces spasticity and improves motor function of fingers.

Keywords

Botulinum toxins type A Stroke Upper extremity Rehabilitation 

Notes

Conflict of interest

The authors declare no conflict of interest. Funding for this study was provided by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science.

References

  1. 1.
    American Heart Association (2004) 2004 Heart and Stroke Statistical Update. American Heart Association , DallasGoogle Scholar
  2. 2.
    Dobkin B (1996) Neurologic Rehabilitation. F.A. Davis Company, PhiladelphiaGoogle Scholar
  3. 3.
    Lundstrom E, Terent A, Borg J (2008) Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol 15:533–539. doi: 10.1111/j.1468-1331.2008.02114.x PubMedCrossRefGoogle Scholar
  4. 4.
    Sommerfeld DK, Eek EU, Svensson AK, Holmqvist LW, von Arbin MH (2004) Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 35:134–139. doi: 10.1161/01.STR.0000105386.05173.5E PubMedCrossRefGoogle Scholar
  5. 5.
    Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK (2002) Prevalence of spasticity post stroke. Clin Rehabil 16:515–522PubMedCrossRefGoogle Scholar
  6. 6.
    Mayer NH, Esquenazi A, Childers MK (1997) Common patterns of clinical motor dysfunction. Muscle Nerve Suppl 6:S21–S35PubMedCrossRefGoogle Scholar
  7. 7.
    Nakayama H, Jorgensen HS, Raaschou HO, Olsen TS (1994) Recovery of upper extremity function in stroke patients: the Copenhagen Stroke Study. Arch Phys Med Rehabil 75:394–398PubMedCrossRefGoogle Scholar
  8. 8.
    Chang CL, Munin MC, Skidmore ER, Niyonkuru C, Huber LM, Weber DJ (2009) Effect of baseline spastic hemiparesis on recovery of upper-limb function following botulinum toxin type A injections and postinjection therapy. Arch Phys Med Rehabil 90:1462–1468. doi: 10.1016/j.apmr.2009.03.008 PubMedCrossRefGoogle Scholar
  9. 9.
    Simpson DM, Alexander DN, O’Brien CF, Tagliati M, Aswad AS, Leon JM et al (1996) Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 46:1306–1310PubMedCrossRefGoogle Scholar
  10. 10.
    Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M et al (2002) Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 347:395–400. doi: 10.1056/NEJMoa011892 PubMedCrossRefGoogle Scholar
  11. 11.
    Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J et al (2000) A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 31:2402–2406PubMedCrossRefGoogle Scholar
  12. 12.
    Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM (2000) Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 69:217–221PubMedCrossRefGoogle Scholar
  13. 13.
    Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B et al (2008) Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 70:1691–1698. doi: 10.1212/01.wnl.0000311391.00944.c4 PubMedCrossRefGoogle Scholar
  14. 14.
    Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M et al (2010) Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin 26:1983–1992. doi: 10.1185/03007995.2010.497103 PubMedCrossRefGoogle Scholar
  15. 15.
    Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M et al (2010) Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol 257:1330–1337. doi: 10.1007/s00415-010-5526-3 PubMedCrossRefGoogle Scholar
  16. 16.
    Takekawa T, Kakuda W, Taguchi K, Ishikawa A, Sase Y, Abo M (2012) Botulinum toxin type A injection, followed by home-based functional training for upper limb hemiparesis after stroke. Int J Rehabil Res 35:146–152. doi: 10.1097/MRR.0b013e3283527f4a PubMedCrossRefGoogle Scholar
  17. 17.
    Drug Interview Form, Botox® Injection 50 (2010) Botox® Injection 100, 15th edn. Glaxo Smith Kline Co., Chennai (in Japanese)Google Scholar
  18. 18.
    Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology (2009) Spasticity in Adults. National guidelines, LondonGoogle Scholar
  19. 19.
    Bohannon RW, Smith MB (1987) Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67:206–207PubMedGoogle Scholar
  20. 20.
    Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S (1975) The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance. Scand J Rehabil Med 7:13–31PubMedGoogle Scholar
  21. 21.
    Morris DM, Uswatte G, Crago JE, Cook EW 3rd, Taub E (2001) The reliability of the wolf motor function test for assessing upper extremity function after stroke. Arch Phys Med Rehabil 82:750–755. doi: 10.1053/apmr.2001.23183 PubMedCrossRefGoogle Scholar
  22. 22.
    Wolf SL, Thompson PA, Winstein CJ, Miller JP, Blanton SR, Nichols-Larsen DS et al (2010) The EXCITE stroke trial: comparing early and delayed constraint-induced movement therapy. Stroke 41:2309–2315. doi: 10.1161/STROKEAHA.110.588723 PubMedCrossRefGoogle Scholar
  23. 23.
    Sheean G, Lannin NA, Turner-Stokes L, Rawicki B, Snow BJ, Cerebral Palsy Institute (2010) Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol 17(Suppl 2):74–93. doi: 10.1111/j.1468-1331.2010.03129.x PubMedCrossRefGoogle Scholar
  24. 24.
    Sawada H, Ishikawa A, Takekawa T, Kakuda W, Kawashima K, Abo M (2011) Botulinum toxin type A injection combined with self-training proposed by occupational therapists for spastic upper limb hemiparesis after stroke (in Japanese). Tokyo Jikei-kai Ika Daigaku Zasshi 126:99–109Google Scholar
  25. 25.
    Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N et al (2010) BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol Assess 14: 1–113, iii–iv. doi: 10.3310/hta14260
  26. 26.
    Bakheit AM, Zakine B, Maisonobe P, Aymard C, Fhedoroff K, Hefter H et al (2010) The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey. Int J Rehabil Res 33:199–204. doi: 10.1097/MRR.0b013e328332f5e0 PubMedCrossRefGoogle Scholar
  27. 27.
    Elia AE, Filippini G, Calandrella D, Albanese A (2009) Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord 24:801–812. doi: 10.1002/mds.22452 PubMedCrossRefGoogle Scholar
  28. 28.
    Hesse S, Werner C (2003) Poststroke motor dysfunction and spasticity: novel pharmacological and physical treatment strategies. CNS Drugs 17:1093–1107PubMedCrossRefGoogle Scholar
  29. 29.
    Francis HP, Wade DT, Turner-Stokes L, Kingswell RS, Dott CS, Coxon EA (2004) Does reducing spasticity translate into functional benefit? An exploratory meta-analysis. J Neurol Neurosurg Psychiatry 75:1547–1551. doi: 10.1136/jnnp.2003.025551 PubMedCrossRefGoogle Scholar
  30. 30.
    Sun SF, Hsu CW, Sun HP, Hwang CW, Yang CL, Wang JL (2010) Combined botulinum toxin type A with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study. Neurorehabil Neural Repair 24:34–41. doi: 10.1177/1545968309341060 PubMedCrossRefGoogle Scholar
  31. 31.
    Cardoso E, Pedreira G, Prazeres A, Ribeiro N, Melo A (2007) Does botulinum toxin improve the function of the patient with spasticity after stroke? Arq Neuropsiquiatr 65:592–595PubMedCrossRefGoogle Scholar
  32. 32.
    Wang HC, Hsieh LF, Chi WC, Lou SM (2002) Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients. Am J Phys Med Rehabil 81:272–278PubMedCrossRefGoogle Scholar

Copyright information

© Belgian Neurological Society 2013

Authors and Affiliations

  • Toru Takekawa
    • 1
  • Masahiro Abo
    • 1
  • Kazuaki Ebihara
    • 1
  • Kensuke Taguchi
    • 1
  • Yousuke Sase
    • 1
  • Wataru Kakuda
    • 1
  1. 1.Department of Rehabilitation MedicineThe Jikei University School of MedicineTokyoJapan

Personalised recommendations